

# Archived Document

This archived document is no longer being reviewed through the CLSI Consensus Document Development Process. However, this document is technically valid as of January 2021. Because of its value to the laboratory community, it is being retained in CLSI's library.



March 2014

---

## H52-A2

### Red Blood Cell Diagnostic Testing Using Flow Cytometry; Approved Guideline—Second Edition

This guideline addresses the diagnostic red blood cell (RBC) assays performed as fluorescence-based assays on a flow cytometry platform; including testing procedures for fetomaternal hemorrhage detection, paroxysmal nocturnal hematuria screening, membrane defect anemia testing for hereditary spherocytosis, and nucleated RBC counting. Points of validation and quality control, and caveats of interpretation are also discussed.

---

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## Appeals Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeals, documented in the CLSI Standards Development Policies and Processes, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

500 West Valley Road, Suite 2500

Wayne, PA 19087 USA

T: +1.610.688.0100

F: +1.610.688.0700

[www.clsi.org](http://www.clsi.org)

[standard@clsi.org](mailto:standard@clsi.org)

ISBN 1-56238-957-2 (Print)  
ISBN 1-56238-958-0 (Electronic)  
ISSN 1558-6502 (Print)  
ISSN 2162-2914 (Electronic)

H52-A2  
Vol. 34 No. 5  
Replaces H52-A  
Vol. 21 No. 26

---

## Red Blood Cell Diagnostic Testing Using Flow Cytometry; Approved Guideline—Second Edition

Volume 34 Number 5

Bruce H. Davis, MD, FCAP  
Mike Keeney, ART, FCSMLS(D)  
Ross Brown, PhD  
Andrea J. Illingworth, MS, H(ASCP), CQYM  
May-Jean King, PhD  
Belinda Kumpel, PhD  
Emily Riehm Meier, MD, FAAP  
S. Gerald Sandler, MD, FACP, FCAP  
Beth H. Shaz, MD  
D. Robert Sutherland, MSc

### Abstract

Clinical and Laboratory Standards Institute document H52-A2—*Red Blood Cell Diagnostic Testing Using Flow Cytometry; Approved Guideline—Second Edition* addresses the diagnostic RBC assays performed as fluorescence-based assays on a flow cytometry platform. Preferred and alternative testing procedures for fetomaternal hemorrhage detection, paroxysmal nocturnal hematuria screening, membrane defect anemia testing for hereditary spherocytosis, and nucleated RBC counting are reviewed. Preferred testing methods, points of validation and QC, and caveats of interpretation are discussed from the perspectives of laboratory practitioners, diagnostic test developers, and regulators. Where appropriate, this guideline integrates current statements of other relevant organizations, such as the International Council for Standardization in Haematology.

Clinical and Laboratory Standards Institute (CLSI). *Red Blood Cell Diagnostic Testing Using Flow Cytometry; Approved Guideline—Second Edition*. CLSI document H52-A2 (ISBN 1-56238-957-2 [Print]; ISBN 1-56238-958-0 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2014.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org). If you or your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: [customerservice@clsi.org](mailto:customerservice@clsi.org); Website: [www.clsi.org](http://www.clsi.org).



CLINICAL AND  
LABORATORY  
STANDARDS  
INSTITUTE®

Copyright ©2014 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

### **Suggested Citation**

CLSI. *Red Blood Cell Diagnostic Testing Using Flow Cytometry; Approved Guideline—Second Edition*. CLSI document H52-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.

### **Previous Editions:**

April 2000, January 2001

### **Reaffirmed:**

June 2016

### **Archived:**

January 2021

ISBN 1-56238-957-2 (Print)  
ISBN 1-56238-958-0 (Electronic)  
ISSN 1558-6502 (Print)  
ISSN 2162-2914 (Electronic)

## Committee Membership

### Consensus Committee on Hematology

**Richard A. Marlar, PhD**  
**Chairholder**  
**Oklahoma City VA Medical Center**  
**Oklahoma City, Oklahoma, USA**

**Mike Keeney, ART, FCSMLS(D)**  
**Vice-Chairholder**  
**London Health Sciences Center**  
**London, Ontario, Canada**

Kathleen M. Curran, BSMT  
 New York State Department of Health  
 Albany, New York, USA

Ian A. Giles, MD  
 Sysmex America, Inc.  
 Mundelein, Illinois, USA

Robert C. Gosselin, CLS  
 University of California, Davis Health  
 System  
 Sacramento, California, USA

Hans J. Hoffmann, PhD  
 Abbott GmbH  
 Wiesbaden-Delkenheim, Germany

Loveleen Chatha Kang, MD  
 College of American Pathologists  
 Northfield, Illinois, USA

### Document Development Committee on RBC Diagnostic Testing Using Flow Cytometry

**Bruce H. Davis, MD, FCAP**  
**Co-Chairholder**  
**Trillium Diagnostics, LLC**  
**Bangor, Maine, USA**

**Mike Keeney, ART, FCSMLS(D)**  
**Co-Chairholder**  
**London Health Sciences Center**  
**London, Ontario, Canada**

Ross Brown, PhD  
 Royal Prince Alfred Hospital  
 Camperdown, Vic., New South Wales,  
 Australia

Andrea J. Illingworth, MS,  
 H(ASCP), CQYM  
 Dahl-Chase Diagnostic Services  
 Bangor, Maine, USA

May-Jean King, PhD  
 NHS Blood and Transplant  
 Bristol, England, United Kingdom

Beth H. Shaz, MD  
 New York Blood Center  
 New York, New York, USA

**Staff**  
 Clinical and Laboratory Standards  
 Institute  
 Wayne, Pennsylvania, USA

Luann Ochs, MS  
*Senior Vice President – Operations*

Jennifer K. Adams, MT(ASCP), MSHA  
*Staff Liaison*

Megan L. Tertel, MA  
*Editor*

Joanne P. Christopher, MA  
*Assistant Editor*

### Acknowledgments

CLSI, the Consensus Committee on Hematology, and the Document Development Committee on RBC Diagnostic Testing Using Flow Cytometry gratefully acknowledge the following volunteers for their important contributions to the development of this document:

Belinda Kumpel, PhD, NHS Blood and Transplant, Bristol, England, United Kingdom  
 Emily Riehm Melick, MD, FAAP, Children's National Medical Center, Washington, DC, USA  
 S. Gerald Sandler, MD, FACP, FCAP, Georgetown University Hospital, Washington, DC, USA  
 D. Robert Sutherland, MSc, Toronto General Hospital, Toronto, Ontario, Canada

CLSI, the Consensus Committee on Hematology, and the Document Development Committee on RBC Diagnostic Testing Using Flow Cytometry thank James D. Hoyer, MD (Department of Pathology, Mayo Foundation) for undertaking retrospective analysis of the eosin-5-maleimide binding results obtained in one year from hereditary spherocytosis (HS) patients' samples sent to his laboratory. His analysis has calculated the ratios (unpublished data) presented in Table 3 of H52, as well as provided additional support for detecting patients of very mild HS whose RBCs could give fluorescence readings in the gray zone.

## Contents

Abstract.....	i
Committee Membership.....	iii
Foreword.....	vii
1 Scope.....	1
2 Introduction.....	1
3 Standard Precautions.....	2
4 Terminology.....	2
4.1 A Note on Terminology.....	2
4.2 Definitions.....	2
4.3 Abbreviations and Acronyms.....	6
5 Specimen Collection, Handling, and Storage.....	7
5.1 Patient Information.....	7
5.2 Specimen Collection Techniques.....	7
5.3 Specimen Integrity.....	8
5.4 Specimen Evaluation.....	8
5.5 Specimen Storage.....	9
6 Standardized Instrument Calibration and Setup.....	9
6.1 Sample Quality Control Procedures.....	10
6.2 Preparation of Negative Control Specimen(s).....	10
6.3 Preparation of Positive Controls.....	11
7 Paroxysmal Nocturnal Hemoglobinuria: Cellular Defects and Clinical Implications.....	12
7.1 Traditional Testing for Paroxysmal Nocturnal Hemoglobinuria and Evolution of Testing by Flow Cytometry.....	12
7.2 Red Blood Cell Analysis.....	13
7.3 External Quality Assessment.....	28
8 Red Blood Cell Membrane Diseases: Cellular Defects and Clinical Implications.....	29
8.1 Traditional Testing for Red Blood Cell Protein Defects.....	30
8.2 Preexamination (Preanalytical) Considerations.....	31
8.3 Examination (Analytical) Considerations.....	36
8.4 Postexamination (Postanalytical) Considerations.....	39
8.5 Limitations.....	41
8.6 Quality Control.....	41
9 Fetomaternal Hemorrhage: Detection and Clinical Implications.....	41
9.1 Caveats of Interpretation.....	42
9.2 Clinical Management Requirements.....	43
9.3 Qualitative or Screening Methods for RhD-Positive Red Blood Cells.....	43
9.4 Semiquantitative Nonflow Cytometric Methods.....	45
9.5 Quantitative Flow Cytometry.....	48
9.6 Detection of F-cells in Hemoglobinopathies and Other Diseases.....	58

**Contents (Continued)**

10	Detection of Nucleated Red Blood Cells .....	59
10.1	Traditional Methods of Enumeration of Nucleated Red Blood Cells .....	60
10.2	Preexamination (Preanalytical) Considerations .....	60
10.3	Examination (Analytical) Considerations .....	61
10.4	Postexamination (Postanalytical) Considerations .....	64
10.5	Limitations .....	64
	References.....	65
	Appendix A. Instrument Setup and Quality Control of Instrument Performance.....	77
	Appendix B. Troubleshooting the Paroxysmal Nocturnal Hemoglobinuria Red Blood Cell Assay ..	85
	Appendix C. Differential Diagnosis Using the Eosin-5-Maleimide Binding Test .....	89
	The Quality Management System Approach .....	94
	Related CLSI Reference Materials .....	95

## Foreword

The recommendations contained herein address both methods in daily use in diagnostic clinical flow cytometry (FCM) and methods for verification or calibration of other assays, including automated cell counting instruments.

Presently, there are no universally accepted standards for precision, accuracy, and interlaboratory comparability in FCM. The recommendations provided in this document reflect the committee's understanding of best practices at the time of publication and in accordance with the present guidelines of the International Council for Standardization in Haematology.

This document replaces the first edition of the approved guideline, H52-A, which was published in 2001. Several changes were made in this edition; chief among them is the revision of the document scope from restricted to fetomaternal hemorrhage (FMH) testing methods to a broader scope of all diagnostic assays on RBCs using FCM. These changes reflect both the expansion of diagnostic FCM testing using RBCs and the clinical need to provide guidelines for testing methods not previously covered by CLSI documents. Specifically, this revision expands the discussion of FMH testing to include preferred testing methodology relating to the diagnosis of paroxysmal nocturnal hemoglobinuria and nonimmune membrane-associated hemolytic anemias (hereditary spherocytosis, hereditary pyropoikilocytosis, and ovalocytosis). Additional diagnostic tools to further evaluate anemic conditions by the reliable quantitation of adult F-cells and nucleated RBCs are also included.

## Key Words

Anemia, diagnostic testing, erythrocyte, fetomaternal hemorrhage, flow cytometry, hemolytic anemia, red blood cells

**Note that the trade name Triton™ X-100 is included in Section 9.5.4.1, and the trade name ECD® (PE/Texas Red®) is used in Appendix 1, Section A2.3 of this document. It is Clinical and Laboratory Standards Institute's policy to avoid using a trade name unless the product identified is the only one available, or it serves solely as an illustrative example of the procedure, practice, or material described. In this case, the document development committee and consensus committee believe the trade name is an important descriptive adjunct to the document. In such cases, it is acceptable to use the product's trade name, as long as the words, "or the equivalent" are added to the references. It should be understood that information on this product in this guideline also applies to any equivalent products. Please include in your comments any information that relates to this aspect of H52.**

## Red Blood Cell Diagnostic Testing Using Flow Cytometry; Approved Guideline—Second Edition

### 1 Scope

This document establishes performance guidelines for applying the science of flow cytometry (FCM) to RBC diagnostic testing. It provides guidelines for:

- Specimen collection, handling, and storage
- Procedures for calibrating instruments
- Procedures for QC of blood samples

Specific sections are dedicated to:

- Paroxysmal nocturnal hemoglobinuria (PNH)
- Diseases of RBC shape, including hereditary spherocytosis (HS)
- Detection of fetomaternal hemorrhage (FMH)
- Detection of nucleated RBCs (NRBCs)

This document is intended for use by laboratory practitioners, *in vitro* diagnostic (IVD) device manufacturers concerned with quality laboratory medicine practice, and regulators responsible for clearance of new diagnostic devices and quality laboratory medicine practice.

While there are many other RBC applications, particularly in the area of blood transfusion science or immunohematology, they will not be addressed in this guideline. In addition, it is beyond the scope of this document to establish general performance criteria and reference intervals. Therefore, it is each laboratory's responsibility to establish instrument performance criteria and staining characteristics for its own specific reagents.

### 2 Introduction

FCM is an established technology in both the research and clinical laboratory. Recently, several methodologies that allow for precise identification and enumeration of fetal RBCs in the maternal circulation and of membrane surface marker defects in PNH have been introduced into the routine clinical laboratory. The original osmotic fragility (OF) test for the detection of HS has been replaced in many large centers by the simple and more reproducible eosin-5-maleimide (EMA) binding test. The laborious sugar water and Ham tests have been replaced by direct measurement of decreased or defective phosphatidylinositol-linked proteins by FCM for the diagnosis of PNH. Finally, the detection of NRBCs using a nuclear dye and the pan leukocyte marker CD45 allows accurate enumeration of NRBCs in those samples in which hematology analyzers may have difficulty doing so.

The goal of this document is to describe methodologies and QA procedures that will help ensure precision and accuracy of flow cytometric results appropriate for their use in the clinical laboratory. This document should be used in conjunction with other guidance documents, particularly the 2013 International Council for Standardization in Haematology/International Clinical Cytometry Society (ICSH/ICCS) Validation of Cell-based Fluorescence Assays: Practice Guidelines.<sup>1-5</sup>